Results 251 to 260 of about 11,453 (281)
Anidulafungin versus Fluconazole for Invasive Candidiasis [PDF]
New England Journal of Medicine, 2007 Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole.
Stanley W. Chapman +11 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Anidulafungin: when and how? The clinician’s view
Mycoses, 2011SummaryAnidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage ...
Jomy M. George, Annette C. Reboli
openaire +2 more sources
Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin
The Journal of Clinical Pharmacology, 2005There is considerable interest in combining echinocandin and triazole antifungal agents for treatment of invasive fungal infections; however, information is needed regarding the tolerability and potential for pharmacokinetic interactions. Anidulafungin is a semisynthetic echinocandin, and voriconazole is an extended‐spectrum triazole.
Alice Baruch +3 more
openaire +2 more sources
Expert Opinion on Drug Safety, 2006
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +3 more sources
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +3 more sources
Anidulafungin biliary passage in liver transplant patients
Transplant Infectious Disease, 2022We evaluated the anidulafungin passage in the bile by calculating the bile/plasma concentration ratios, and we assessed whether the ratios were influenced either by the time from administration or day of therapy. To this aim, a multiple linear GEE regression model (SAS software) was used, with the day of therapy and the hour after administration as ...
Adembri, Chiara +5 more
openaire +2 more sources
Anidulafungin: an echinocandin antifungal
Expert Opinion on Investigational Drugs, 2004Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
openaire +2 more sources
Anidulafungin: a drug evaluation of a new echinocandin
Expert Opinion on Pharmacotherapy, 2008Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium.The intention of this review is to provide a drug evaluation of anidulafungin, including its spectrum of activity ...
Jomy M Joseph +2 more
openaire +3 more sources
Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C.
Catiana Dudiuk +10 more
semanticscholar +1 more source
BACKGROUND Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C.
Catiana Dudiuk +10 more
semanticscholar +1 more source
Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin
Journal of pharmacy and practice, 2020Background: Case reports and pharmacokinetic data suggest off-label echinocandin dosing may be needed to reach adequate serum concentrations in obese patients. Few outcome studies exist evaluating this population.
Mary Hutton +3 more
semanticscholar +1 more source
The Pediatric Infectious Disease Journal, 2019
Background: Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC.
E. Roilides +8 more
semanticscholar +1 more source
Background: Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC.
E. Roilides +8 more
semanticscholar +1 more source